

Applicants: Tae-Wan Kim and Kwang Mook Jung

Serial No.: 10/623,442

Filed: July 18, 2003

Page 10

In accordance with their duty of disclosure under 37 C.F.R. §1.56, applicants submit this Supplemental Information Disclosure Statement to supplement the Information Disclosure Statement previously filed October 20, 2003.

Applicants direct the Examiner's attention to the following references which are listed on the Form PTO-1449 attached hereto as **Exhibit A**.

1. Printout of the Qbiogene website <<http://www.qbiogene.com/products/transfection/penetratin.shtml>> (**Exhibit B**); and
2. Bonfanti, et al., "p21^{WAF1}-derived Peptides Linked to an Internalization Peptide Inhibit Human Cancer Cell Growth", Cancer Res. 57, 1442-1446 (1997) (**Exhibit C**).

Applicants request that the Examiner consider the references listed on the Form PTO-1449 and make them of record in the subject application.

In accordance with 37 C.F.R. §1.17(p), the fee for filing this Supplemental Information Disclosure Statement is \$180.00. A check including this amount is enclosed.

Sequence Listing

Applicant submits herewith (i) a paper copy of the new sequence listing (**Exhibit D**), (ii) a computer readable form (C.R.F.) of the

Applicants: Tae-Wan Kim and Kwang Mook Jung
Serial No.: 10/623,442
Filed: July 18, 2003
Page 11

new sequence listing and (iii) a Statement in Accordance with 37 C.F.R. §1.821(f) certifying that the C.R.F. and written sequence listing contain the same sequence information (**Exhibit E**). Applicant has also amended the specification to incorporate the new sequence listing.

Summary

For the reasons set forth hereinabove, applicants respectfully maintain that claim 4, as amended, is in condition for allowance.

No fee, other than the \$510.00 fee for a three-month extension of time and the \$180.00 fee for filing a Supplemental Information Disclosure Statement, is deemed necessary in connection with the filing of this Amendment. Accordingly, a check for \$690.00 is enclosed. However, if any additional fee is required, authorization is hereby given to charge the amount of such fee to Deposit Account No. 03-3125.

Applicants: Tae-Wan Kim and Kwang Mook Jung


Serial No.: 10/623,442

Filed: July 18, 2003

Page 12

If a telephone interview would be of assistance in advancing prosecution of the subject application, applicants' undersigned attorney invites the Examiner to telephone him at the number provided below.

Respectfully submitted,



John P. White
Registration No. 28,678
Attorney for Applicants
Cooper & Dunham LLP
1185 Avenue of the Americas
New York, New York 10036
(212) 278-0400

I hereby certify that this correspondence is being deposited this date with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to:

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450




John P. White
Reg. No. 28,678
Date
3/27/07

EXHIBIT A

Form PTO-1449		U.S. Department of Commerce Patent and Trademark Office		Application Number	10/6623,442
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		 APR 02 2007		Filing Date	July 18, 2003
				First Named Inventor	Tae-Wan Kim et al.
				Art Unit	1644
				Examiner Name	Maher M. Haddad
				Attorney Docket No.	66195JPW/JCS
NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			
		Printout of the Qbiogene website < http://www.qbiogene.com/products/transfection/penetratin.shtml >			
		Bonfanti, et al., "p21 ^{WAF1} -derived Peptides Linked to an Internalization Peptide Inhibit Human Cancer Cell Growth", Cancer Res. 57, 1442-1446 (1997)			
EXAMINER SIGNATURE		DATE CONSIDERED			
<small>*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.¹ Applicant's unique citation designation number (optional).² Applicant is to place a checkmark here if English language Translation is attached.</small>					

Applicants: Tae-Wan Kim, et al.
Serial No.: 10/623,442
Filed: July 18, 2003
Exhibit A

EXHIBIT B